• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cells to Society: Year of the Nurse / Global Impact
This study establishes baseline sociodemographic and clinical characteristics of hospitalized patients in Nepal who were experiencing heart failure.     Read more   Maternal Health ...
Source: Johns Hopkins University and Health Systems Archive - February 6, 2020 Category: Nursing Source Type: news

Don't Simply Turn Away
Did you know that there are 35 national health observances that take place during the month of May? To name a few: Hepatitis and Stroke Awareness Month, Mental Health Month, Teen Pregnancy Prevention, National Physical Education and Sport Week, National Bike to School Day and World Autoimmune Awareness Day. There are a total of 213 national health observances throughout the year. Some might ask: "Is of all this necessary?" "Aren't 213 observances a bit of an overkill?" "Why so many?" We often hear these questions because the majority of people don't really understand the hardships, difficulties, and struggles of ot...
Source: Healthy Living - The Huffington Post - May 3, 2016 Category: Consumer Health News Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news